Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?

Gilead has been under pressure over the last year to prove that its new products to treat HIV and cancer will perform well enough to counteract a faster-than-expected decline of its hepatitis C franchise. The third quarter did produce a glimmer of hope—particularly in HIV—but as is often the case with Gilead, the good news was met with some skepticism about the company’s continued growth prospects.